These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1069 related items for PubMed ID: 15337536

  • 1. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW, Schild SE, Vora SA, Halyard MY.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):24-9. PubMed ID: 15337536
    [Abstract] [Full Text] [Related]

  • 2. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):415-9. PubMed ID: 15667961
    [Abstract] [Full Text] [Related]

  • 3. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Mar 01; 61(3):714-24. PubMed ID: 15708249
    [Abstract] [Full Text] [Related]

  • 4. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA.
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1140-50. PubMed ID: 16198506
    [Abstract] [Full Text] [Related]

  • 5. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):1003-10. PubMed ID: 15752879
    [Abstract] [Full Text] [Related]

  • 6. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 7. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E.
    Cancer J Sci Am; 1997 Nov 01; 3(2):78-87. PubMed ID: 9099457
    [Abstract] [Full Text] [Related]

  • 8. Failure pattern implications following external beam irradiation of prostate cancer: long-term follow-up and indications of cure.
    Hanlon AL, Hanks GE.
    Cancer J; 2000 Apr 01; 6 Suppl 2():S193-7. PubMed ID: 10803836
    [Abstract] [Full Text] [Related]

  • 9. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA, Buchsbaum JC, Elshaikh M, Reddy CA, Zippe C, Klein EA.
    Cancer; 2002 Dec 01; 95(11):2302-7. PubMed ID: 12436435
    [Abstract] [Full Text] [Related]

  • 10. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
    Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):993-1002. PubMed ID: 15752878
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):15-23. PubMed ID: 15337535
    [Abstract] [Full Text] [Related]

  • 13. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T, Kitamoto Y, Saito J, Harashima K, Nakano T, Ito K, Yamamoto T, Kurokawa K, Yamanaka H, Takahashi M, Mitsuhashi N, Niibe H.
    Int J Radiat Oncol Biol Phys; 2004 Jun 01; 59(2):372-9. PubMed ID: 15145150
    [Abstract] [Full Text] [Related]

  • 14. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1520-9. PubMed ID: 15050332
    [Abstract] [Full Text] [Related]

  • 15. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2005 Jan 01; 61(1):32-43. PubMed ID: 15629591
    [Abstract] [Full Text] [Related]

  • 16. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
    Chautard D, Cellier P, Dalifard I, Pabot du Chatelard P, Chaussis F, Vielle B, Soret JY, Passagot J, Courte C, Daver A.
    Prog Urol; 2002 Jun 01; 12(3):421-8. PubMed ID: 12189749
    [Abstract] [Full Text] [Related]

  • 17. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL, McGrath S, Martinez AA, Vicini FA, Kestin LL.
    Int J Radiat Oncol Biol Phys; 2006 Dec 01; 66(5):1430-9. PubMed ID: 16765527
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
    D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
    Cancer; 2002 Jul 15; 95(2):281-6. PubMed ID: 12124827
    [Abstract] [Full Text] [Related]

  • 20. Impact of percent positive random biopsies on biochemical outcome in prostate cancer patients treated with external beam radiotherapy with or without androgen deprivation.
    Igdem S, Abacioglu U, Cetin I, Alco G, Akgun Z, Sengoz M, Bekiroglu N, Turkan S, Okkan S.
    J BUON; 2009 Jul 15; 14(4):629-34. PubMed ID: 20148454
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.